



Oxidative Modification of Tryptophan-Containing Peptides

Petersen, Jonas; Christensen, Pia Katrine; Nielsen, Mathias T; Mortensen, Kim T.; Komnatny, Vitaly V.; Nielsen, Thomas E.; Qvortrup, Katrine

Published in:

A C S Combinatorial Science

Link to article, DOI:

[10.1021/acscombsci.8b00014](https://doi.org/10.1021/acscombsci.8b00014)

Publication date:

2018

Document Version

Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):


Petersen, J., Christensen, P. K., Nielsen, M. T., Mortensen, K. T., Komnatny, V. V., Nielsen, T. E., & Qvortrup, K. (2018). Oxidative Modification of Tryptophan-Containing Peptides. *A C S Combinatorial Science*, 20(6). <https://doi.org/10.1021/acscombsci.8b00014>

General rights


Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **Oxidative Modification of Tryptophan-Containing Peptides**2 Jonas Petersen,[†] Katrine E. Christensen,[†] Mathias T. Nielsen,[†] Kim T. Mortensen,[†] Vitaly V. Komnatny,[†]
3 Thomas E. Nielsen,^{†,‡,§} and Katrine Qvortrup^{*,†} 4 [†]Department of Chemistry, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark5 [‡]Department of Immunology and Microbiology, University of Copenhagen, DK-2200 Copenhagen, Denmark6 [§]Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore 6375517  Supporting Information8 **ABSTRACT:** We herein present a broadly useful method for
9 the chemoselective modification of a wide range of
10 tryptophan-containing peptides. Exposing a tryptophan-
11 containing peptide to 2,3-dichloro-5,6-dicyano-1,4-benzoqui-
12 none (DDQ) resulted in a selective cyclodehydration between
13 the peptide backbone and the indole side chain of tryptophan
14 to form a fully conjugated indolyl-oxazole moiety. The modified peptides show a characteristic and significant emission maximum
15 at 425 nm, thus making the method a useful strategy for fluorescence labeling.16 **KEYWORDS:** solid-phase peptide synthesis, fluorescent labeling, tryptophan, site-selective protein modification

Chemoselective modification of tryptophan-containing peptides



17 ■ INTRODUCTION

18 Fluorescence labeling of proteins and peptides is fundamental
19 for the study of biological systems, as it can provide detailed
20 visualization of complex cellular processes.¹ The visualization of
21 biological processes has been crucial for our understanding of
22 molecular dynamics and the development of new potent drugs.
23 Nowadays, the most common approach to fluorescence
24 labeling of proteins comprises the introduction of fluorescent
25 small molecules to the nucleophilic side chain of lysine, serine,
26 threonine, or cysteine residues in a peptide or protein of
27 interest.² However, such strategies often suffer from poor site
28 selectivity, where multiple residues are modified. Though less
29 established, chemoselective functionalization of other residues,
30 such as methionine,³ glutamine,⁴ arginine,⁵ N-terminal serine/
31 threonine,⁶ tyrosine,⁷ and tryptophan,⁸ has been described.
32 Among these residues, tryptophan is particularly interesting
33 because of its scarce abundance in proteins. With a natural
34 abundance of only 1.09%,⁹ many proteins of interest will
35 contain only a single or few tryptophan residues accessible for
36 functionalization, thus enabling high control of the position for
37 modification. Furthermore, the relative large size of organic
38 dyes, including undesired physiochemical properties may give
39 rise to several challenges, that compromise the biologically
40 activity of the labeled target. Therefore, labeling strategies that
41 introduce minimal structural perturbation to the peptide of
42 interest is of high importance.43 Herein, we describe our efforts toward the oxidative
44 modification of small peptides containing tryptophan. The
45 conjugated nature of the generated indolyl-oxazole moiety
46 emits blue-fluorescence,¹⁰ which may advantageously be
47 utilized for spectroscopic studies of biological systems. For
48 instance, the indolyl-oxazole moiety of diazonamide A
49 derivatives has been utilized as intrinsic fluorophores for in
50 vitro cellular uptake studies.¹¹ In addition, the indolyl-oxazole51 scaffold is present in a variety of naturally occurring biologically
52 active compounds including those shown in Figure 1,^{12–15} as
53 well as cyclic derivatives such as the diazonamides.¹¹

■ RESULTS AND DISCUSSION

54
55 Using standard reagents for solid-phase peptide synthesis, the
56 HMBA linker was easily immobilized and synthetically
57 elaborated on an amino-functionalized ChemMatrix resin
58 (Table 1). Initially, a range of conditions for the oxidative
59 cyclodehydration of model compound 6 (Scheme 1) was
60 examined.¹⁶ Oxidation of the α -carbon of indoles has been
61 performed with the dehydrogenating agent DDQ to form the
62 keto-indole derivative.¹⁶ Therefore, it was expected that DDQ
63 could be a suitable reagent for the oxidative cyclodehydration of
64 tryptophan. Furthermore, cyclodehydration of keto-indoles has
65 been carried out with a mixture of triphenylphosphine, metallic
66 iodine, and triethylamine in CH₂Cl₂, to form a conjugated
67 indolyl-oxazole moiety.¹⁷ Various solvents were screened
68 (entries A–G), and it was disclosed that exposure of a
69 tryptophan-containing oligopeptide to DDQ (4 equiv) in
70 MeCN led to near-quantitative conversion into the desired
71 indolyl-oxazole product 9 (Scheme 1). Interestingly, the
72 peptide was fully converted to the desired indolyl-oxazole
73 derivative with only two equivalents of DDQ (entry J). The
74 reaction most likely occurs via the α,β -unsaturated imine 7
75 (Scheme 1). However, in reactions where partial formation of
76 the ketone product 8 was initially observed, it was noted that
77 prolonged reaction times resulted in full conversion to the
78 desired cyclo-dehydrated product 9.

Received: January 30, 2018

Revised: April 13, 2018

Published: May 2, 2018






Figure 1. Biologically active indolyl-oxazole natural products.

Table 1. Chemical Data for the Indolyl-oxazoles 10A–AQ


entry	AA	conditions	solvent	purity ^a (%)	yield ^b (%)	entry	AA	conditions	solvent	purity ^a (%)	yield ^b (%)
A	Ala	DDQ (4 equiv)	toluene	20		W	Asp(OBzl)	DDQ (2 equiv)	CH ₃ CN	48	
B	Ala	DDQ (4 equiv)	THF	40		X	Asp(O <i>t</i> Bu)	DDQ (2 equiv)	CH ₃ CN	81	30
C	Ala	DDQ (4 equiv)	CH ₂ Cl ₂	60		Y	Glu	DDQ (2 equiv)	CH ₃ CN	64	23
D	Ala	DDQ (4 equiv)	DMF	5		Z	Glu(O <i>t</i> Bu)	DDQ (2 equiv)	CH ₃ CN		14
E	Ala	DDQ (4 equiv)	CH ₃ CN	90		AA	Cys(<i>t</i> Bu)	DDQ (2 equiv)	CH ₃ CN	66	17
F	Ala	DDQ (4 equiv)	H ₂ O	0		AB	Cys(<i>S</i> <i>t</i> Bu)	DDQ (2 equiv)	CH ₃ CN	34	
G	Ala	DDQ (4 equiv)	MeOH	5		AC	Ser	DDQ (2 equiv)	CH ₃ CN	81	15
H	Ala	tetrachloro-1,4-benzoquinone (4 equiv)	CH ₃ CN	0		AD	Ser(OBn)	DDQ (2 equiv)	CH ₃ CN	77	19
I	Ala	DDQ (3 equiv)	CH ₃ CN	89		AE	Gln	DDQ (2 equiv)	CH ₃ CN	91	12
J	Ala	DDQ (2 equiv)	CH ₃ CN	88	25	AF	Gln(Trt)	DDQ (2 equiv)	CH ₃ CN	>95	
K	Ala	DDQ (1 equiv)	CH ₃ CN	65		AG	Lys	DDQ (2 equiv)	CH ₃ CN	0	
L	Gly	DDQ (2 equiv)	CH ₃ CN	86	31	AH	Lys(Boc)	DDQ (2 equiv)	CH ₃ CN	>95	13
M	Val	DDQ (2 equiv)	CH ₃ CN	75	15	AI	His	DDQ (2 equiv)	CH ₃ CN	80	10
N	Leu	DDQ (2 equiv)	CH ₃ CN	77	20	AJ	His(Boc)	DDQ (2 equiv)	CH ₃ CN	53	
O	Ile	DDQ (2 equiv)	CH ₃ CN	75	17	AK	Thr	DDQ (2 equiv)	CH ₃ CN	62	12
P	Pro	DDQ (2 equiv)	CH ₃ CN	77	31	AL	Thr(O <i>t</i> Bu)	DDQ (2 equiv)	CH ₃ CN	69	13
Q	Phe	DDQ (2 equiv)	CH ₃ CN	63	24	AM	Asn	DDQ (2 equiv)	CH ₃ CN	>95	
R	Met	DDQ (2 equiv)	CH ₃ CN	76	40	AN	Asn(Trt)	DDQ (2 equiv)	CH ₃ CN	62	25
S	Tyr	DDQ (2 equiv)	CH ₃ CN	81	25	AO	Arg(Pmc)	DDQ (2 equiv)	CH ₃ CN	62	18
T	Tyr(All)	DDQ (2 equiv)	CH ₃ CN	38	16	AP	Ala-Trp-Gly-Pro-Trp-Leu	DDQ (2 equiv)	CH ₃ CN	82	
U	Tyr(OMe)	DDQ (2 equiv)	CH ₃ CN	92	18	AQ	Ala-Trp-Val-Trp-Ile-Trp-Phe	DDQ (3 equiv)	CH ₃ CN	75	
V	Asp	DDQ (2 equiv)	CH ₃ CN	45	15						

^aCrude purities. ^bAll compounds were purified by prepHPLC before yield determination and NMR analysis.


79 The sequence tolerance of the site-selective tryptophan
80 oxidation protocol was investigated through the synthesis of a

combinatorial library of natural amino acids and common 81
protective groups (entry L-AO). Gratifyingly, the developed 82

Scheme 1. Synthesis of Indolyl-oxazole-Functionalized Peptide 9



Scheme 2. Synthesis of Peptides 11(J,L-AO)



83 protocol showed compatibility with a wide range of peptides
84 and generally only the desired product was observed by UP-
85 LCMS (see [Supporting Information](#)). Unfortunately, non-
86 protected lysine residues were not tolerated (entry AG). Here a
87 range of byproducts was observed by UPLC, including a
88 nucleophilic addition of the lysine side-chain amino group to
89 the conjugated imine (7) as well as a Michael reaction between
90 the amino group and DDQ.

91 The isolated yields of indolyl oxazole peptides are in the
92 range typically observed for solid-phase synthesis followed by
93 preparative HPLC purification. From our results, we cannot
94 identify a correlation between purity and isolated yields neither
95 is there apparent structure-yield correlation.

96 Furthermore, the methodology was investigated for peptides
97 containing more than one tryptophan residue (entry AP–AQ).
98 Using two and three equivalents of DDQ, respectively, peptides
99 containing two or three indolyl-oxazole moieties were obtained
100 (see [Supporting Information](#)).

101 In order to investigate the potential of the technique for
102 fluorescent labeling, the fluorescence properties of the indolyl-
103 oxazole containing peptide 10(J,L-AO) was measured and
104 compared to the emission spectrum of the corresponding
105 nonoxidized peptides 11(J,L-AO), [Scheme 2](#).

106 As shown in [Figure 2](#), the indolyl-oxazole containing peptides
107 show a remarkably change in fluorescence with a distinct band
108 now appearing at 425 nm. Importantly, this absorption is not
109 affected by the presence of aromatic side chain functionalities in
110 naturally occurring amino acids.

111 Having identified conditions allowing for oxidative cyclo-
112 dehydration of tryptophan in various peptides, we sought to
113 demonstrate the use of this methodology in the labeling of
114 biological relevant peptides. GLP-1 is a 30 amino acid-




Figure 2. Fluorescence measurement of compound 10J,L-AO and 11J,L-AO.

115 containing peptide hormone that possesses several pharmaco-
116 logical properties, making it a subject of intensive investigation.
117 Gratifyingly, when exposing GLP-1(12), to the DDQ
118 conditions the desired fluorescence labeled indolyl-oxazole
119 analog 13 was formed ([Figure 2](#)) with a satisfactory conversion
120 of 85%, as confirmed by HPLC.

121 Currently, the methodology has only been demonstrated for
122 immobilized peptides that tolerate acetonitrile. It would be
123 desirable to adapt this chemistry to aqueous conditions, thereby
124 allowing indolyl-oxazole formation in proteins. This would




Figure 3. Fluorescent labeling of GLP-1.

125 require the development of a more stable dehydrogenation
126 reagent, which resists hydrolysis in aqueous solutions.

127 CONCLUSIONS

128 In summary, we report a method that allows for the
129 chemoselective labeling of tryptophan-containing peptide
130 residues. DDQ-mediated oxidative cyclization leads to the
131 installation of an indolyl-oxazole moiety with unique
132 fluorescence properties. We further demonstrate that the
133 indolyl-oxazole moiety selectively may be installed in a
134 pharmaceutically relevant peptide, thereby emphasizing the
135 important potential of the methodology to illuminate biological
136 mechanism of relevance to drug discovery.

137 EXPERIMENTAL SECTION

138 **General Methods.** All reagents and materials used were
139 purchased from ordinary chemical suppliers and were used
140 without purification. The solvents used were of standard HPLC
141 grade. Solid-phase synthesis was carried out using plastic-
142 syringe techniques. Flat-bottomed PE-syringes were fitted with
143 PP-filters and situated in Teflon valves equipped with Teflon
144 tubing allowing for a moderate vacuum to be applied to the
145 syringes.

146 Yields of solid-phase synthesis protocols are corrected for salt
147 contents and given as percentage of product mass recovery to
148 the theoretical product loading mass, calculated from the resin
149 loading (4 mmol/g) as specified by the supplier.

150 Products were analyzed on a Waters Alliance reverse-phase
151 HPLC system consisting of a Waters 2695 Separations Module
152 equipped with a Symmetry C18 column (3.5 μm , 4.6 \times 75 mm,
153 column temp 25 $^{\circ}\text{C}$, flow rate 1 mL/min) and a Waters
154 Photodiode Array Detector (detecting at 215 nm). Elution was
155 carried out in a linear reversed phase gradient fashion (gradient
156 A: 0% organic for 0.2 min, 0% organic to 100% organic in 10

min, hold for 1 min, 100% organic to 0% organic in 0.3 min, 157
hold for 1.5 min, gradient B: 0% organic for 0.2 min, 0% 158
organic to 40% organic in 10 min, 40% organic to 100% organic 159
in 0.8 min, hold for 1 min, 100% organic to 0% organic in 0.3 160
min, hold for 1.5 min) combining water and acetonitrile 161
(buffered with 0.1% (v/v) TFA). 162

Preparative RP-HPLC was carried out on a Waters Alliance 163
reverse-phase HPLC system consisting of a Waters 2545 Binary 164
Gradient Module equipped with an xBridge TM. 165

Prep BEH130 C18 column OBDTM (5 μm , 19 \times 100 mm, 166
column temp 25 $^{\circ}\text{C}$, flow rate 20 mL/min), a Waters 167
Photodiode Array Detector (detecting at 210–600 nm), a 168
Waters UV Fraction Manager and a Waters 2767 Sample 169
Manager. Elution was carried out in a linear reversed phase 170
gradient fashion combining water and acetonitrile (buffered 171
with 0.2% (v/v) TFA). 172

1D and 2D NMR spectra were recorded using a Varian Unity 173
Inova-500 MHz, a Varian Mercury-300 MHz instrument, a 174
Bruker Ascend-400 MHz instrument equipped with a 5 mm 175
Prodigy cryoprobe or a Bruker Avance-800 MHz instrument, 176
equipped with a 5 mm cryoprobe TCI, in DMSO- d_6 or CDCl $_3$ 177
using the residual DMSO or CHCl $_3$ solvent peaks, respectively, 178
as the internal standard. All ^{13}C NMR spectra were proton 179
decoupled. DQF-COSY, HSQC, HMBC, and 2D NOESY 180
spectra were acquired using standard pulse sequences. 181

LC-DAD-HRMS was performed on an Agilent 1100 LC 182
system equipped with a Agilent Technologies Diode Array 183
Detector and a Luna C18 column (3 μm , 50 mm \times 2 mm, 184
column temp 40 $^{\circ}\text{C}$, flow rate 400 $\mu\text{L}/\text{min}$). Separation was 185
achieved using a linear reversed phase gradient (20% to 100% 186
organic in 8 min, hold for 2 min, 100% to 20% organic in 1 min, 187
hold for 4 min) again combining water and acetonitrile 188
(buffered with 20 mM HCO $_2\text{H}$). The LC was coupled to a 189
Micromass LCT orthogonal time-of-flight mass spectrometer, 190

191 equipped with Lock Mass probe and operated in positive
192 electrospray mode.

193 **General Solid-Phase Procedures.** The commercial
194 available amino functionalized ChemMatrix (0.4 mmol/g)
195 was washed with DMF. Coupling of the first amino acid
196 building block to the resin was carried out as follows. Dry resin
197 was weighed in a syringe, equipped with a PP-filter. The amino
198 acid (3 equiv) was weighed, dissolved in DMF (0.02 mL/mg
199 resin) and *N*-ethylmorpholine (4 equiv) was added using a
200 microliter pipet. *N*-[(1*H*-Benzotriazol-1-yl)(dimethylamino)-
201 methylene]-*N*-methylmethanaminium tetrafluoroborate *N*-
202 oxide (TBTU, 2.9 equiv) was weighed and likewise added.
203 The solution was transferred to the resin, the swelled resin
204 stirred gently with a spatula and allowed to react for 2 h. The
205 resin was filtered, washed with DMF (×6) and CH₂Cl₂ (×6)
206 and lyophilized. The Fmoc-group was removed by swelling the
207 resin in a solution of piperidine (20% v/v) in DMF for 2 min,
208 filtering and then swelling the resin again in a fresh solution of
209 piperidine (20% v/v) in DMF for 18 min. The resin was
210 washed with DMF (×6) and CH₂Cl₂ (×6) and lyophilized.

211 The oxidatively modified peptides were liberated from the
212 HMBA-functionalized ChemMatrix resin by addition of 4 mL
213 of 0.1 N aqueous NaOH. The syringes were left overnight
214 under vigorous shaking followed by neutralization with 0.1 N
215 HCl (aq). The aqueous solutions containing the peptides were
216 collected by filtration and the resins were washed with water
217 (×5) and MeCN (×5). The purity of the crude reaction
218 mixture was monitored by UPLC-MS. The MeCN and water
219 was removed by evaporation and freeze-drying. The residue was
220 redissolved in 3 mL of DMF, filtrated and purified by
221 preparative RP-HPLC. The solvent was removed from the
222 product-containing fractions by evaporation and freeze-drying
223 before NMR data collection and measurement of the
224 fluorescence properties using a Tecan microplate reader.

225 **Evaluation of Spectroscopic Properties.** The fluores-
226 cence experiments were conducted by soluting each of the
227 peptides in methanol. The fluorescence of the peptides was
228 monitored using a Tecan microplate reader, which first records
229 the absorbance properties to identify the required wavelength
230 for excitation of the compound. The fluorescence was then
231 measured in the arbitrary unit 'Relative Fluorescence Units'
232 (RFU) and plotted against their respective wavelengths. The
233 measurements were acquired setting the gain to 70.

234 ■ ASSOCIATED CONTENT

235 ⓘ Supporting Information

236 The Supporting Information is available free of charge on the
237 ACS Publications website at DOI: [10.1021/acscombsci.8b00014](https://doi.org/10.1021/acscombsci.8b00014).

239 Analytical data (¹H and ¹³C NMR spectra and LC-MS
240 chromatograms) of all compounds synthesized (PDF)

241 ■ AUTHOR INFORMATION

242 Corresponding Author

243 *E-mail: kaqvo@kemi.dtu.dk.

244 ORCID ⓘ

245 Katrine Qvortrup: 0000-0003-3828-2069

246 Notes

247 The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the Carlsberg Foundation, and the Technical
University of Denmark for financial support.

■ REFERENCES

- (1) (a) Jonassen, I.; Havelund, S.; Hoeg-Jensen, T.; Steensgaard, D. B.; Wahlund, P. O.; Ribel, U. Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin. *Pharm. Res.* **2012**, *29*, 2104–2114. (b) Löwik, D. W.; Leunissen, E. H.; van den Heuvel, M.; Hansen, M. B.; van Hest, J. C. Stimulus responsive peptide based materials. *Chem. Soc. Rev.* **2010**, *39*, 3394–3412. (c) Yim, C. B.; Dijkgraaf, I.; Merckx, R.; Versluis, C.; Eek, A.; Mulder, G. E.; Rijkers, D. T.; Boerman, O. C.; Liskamp, R. M. Synthesis of DOTA-Conjugated Multimeric [Tyr³]Octreotide Peptides via a Combination of Cu(I)-Catalyzed "Click" Cycloaddition and Thio Acid/Sulfonyl Azide "Sulfo-Click" Amidation and Their in Vivo Evaluation. *J. Med. Chem.* **2010**, *53*, 3944–3953.
- (2) (a) Takaoka, Y.; Ojida, A.; Hamachi, I. Protein organic chemistry and applications for labeling and engineering in live-cell systems. *Angew. Chem., Int. Ed.* **2013**, *52*, 4088–4106; *Angew. Chem.* **2013**, *125*, 4182–4200. (b) Schoffelen, S.; van Eldijk, M. B.; Rooijackers, B.; Rajmakers, R.; Heck, A. J. R.; van Hest, J. C. M. Metal-free and pH-controlled introduction of azides in proteins. *Chem. Sci.* **2011**, *2*, 701–705.
- (3) (a) Carlsson, F. H. The selective S-alkylation of a methionine residue in an elapid venom cardiotoxin. *Int. J. Biochem.* **1987**, *19*, 915–921. (b) Kramer, J. R.; Deming, T. J. Reversible chemoselective tagging and functionalization of methionine containing peptides. *Chem. Commun.* **2013**, *49*, 5144–5146.
- (4) Fontana, A.; Spolaore, B.; Mero, A.; Veronese, F. M. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. *Adv. Drug Delivery Rev.* **2008**, *60*, 13–28.
- (5) Gauthier, M. A.; Klok, H. A. Arginine-Specific Modification of Proteins with Polyethylene Glycol. *Biomacromolecules* **2011**, *12*, 482–493.
- (6) (a) Geoghegan, K. F.; Stroh, J. G. Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. *Bioconjugate Chem.* **1992**, *3*, 138–146. (b) Ning, X.; Temming, R. P.; Dommerholt, J.; Guo, J.; Ania, D. B.; Debets, M. F.; Wolfert, M. A.; Boons, G. J.; van Delft, F. L. Protein Modification by Strain-Promoted Alkyne–Nitrene Cycloaddition. *Angew. Chem., Int. Ed.* **2010**, *49*, 3065–3068; *Angew. Chem.* **2010**, *122*, 3129–3132.
- (7) (a) Ban, H.; Gavriljuk, J.; Barbas, C. F., III Tyrosine Bioconjugation through Aqueous Ene-Type Reactions: A Click-Like Reaction for Tyrosine. *J. Am. Chem. Soc.* **2010**, *132*, 1523–1525. (b) Ban, H.; Nagano, M.; Gavriljuk, J.; Hakamata, W.; Inokuma, T.; Barbas, C. F., III Facile and Stable Linkages through Tyrosine: Bioconjugation Strategies with the Tyrosine-Click Reaction. *Bioconjugate Chem.* **2013**, *24*, 520–532. (c) Jones, M. W.; Mantovani, G.; Blindauer, C. A.; Ryan, S. M.; Wang, X.; Brayden, D. J.; Haddleton, D. M. Direct Peptide Bioconjugation/PEGylation at Tyrosine with Linear and Branched Polymeric Diazonium Salts. *J. Am. Chem. Soc.* **2012**, *134*, 7406–7413. (d) Tilley, S. D.; Francis, M. B. Tyrosine-Selective Protein Alkylation Using π -Allylpalladium Complexes. *J. Am. Chem. Soc.* **2006**, *128*, 1080–1081.
- (8) (a) Antos, J. M.; Francis, M. B. Selective Tryptophan Modification with Rhodium Carbenoids in Aqueous Solution. *J. Am. Chem. Soc.* **2004**, *126*, 10256–10257. (b) Antos, J. M.; McFarland, J. M.; Iavarone, A. T.; Francis, M. B. Chemoselective Tryptophan Labeling with Rhodium Carbenoids at Mild pH. *J. Am. Chem. Soc.* **2009**, *131*, 6301–6308. (c) Ruiz-Rodríguez, J.; Albericio, F.; Lavilla, R. Postsynthetic Modification of Peptides: Chemoselective C-Arylation of Tryptophan Residues. *Chem. - Eur. J.* **2010**, *16*, 1124–1127. (d) Williams, T. J.; Reay, A. J.; Whitwood, A. C.; Fairlamb, I. J. A mild and selective Pd-mediated methodology for the synthesis of highly fluorescent 2-arylated tryptophans and tryptophan-containing peptides: a catalytic role for Pd⁰ nanoparticles? *Chem. Commun.* **2014**, *50*, 314

- 315 3052–3054. (e) Siti, W.; Khan, A. K.; de Hoog, H. P.; Liedberg, B.;
316 Nallani, M. Photo-induced conjugation of tetrazoles to modified and
317 native proteins. *Org. Biomol. Chem.* **2015**, *13*, 3202–3206. (f) Perekalin,
318 D. S.; Novikov, V. V.; Pavlov, A. A.; Ivanov, I. A.; Anisimova, N. Y.;
319 Kopylov, A. N.; Volkov, D. S.; Seregina, I. F.; Bolshov, M. A.; Kudinov,
320 A. R. Selective Ruthenium Labeling of the Tryptophan Residue in the
321 Bee Venom Peptide Melittin. *Chem. - Eur. J.* **2015**, *21*, 4923–4925.
322 (g) Chen, Z.; Popp, B. V.; Bovet, C. L.; Ball, Z. T. Site-Specific Protein
323 Modification with a Dirhodium Metallopeptide Catalyst. *ACS Chem.*
324 *Biol.* **2011**, *6*, 920–925. (h) Mendive-Tapia, L.; Preciado, S.; Garcia, J.;
325 Ramon, R.; Kielland, N.; Albericio, F.; Lavilla, R. New peptide
326 architectures through C–H activation stapling between tryptophan–
327 phenylalanine/tyrosine residues. *Nat. Commun.* **2015**, *6*, 7160.
328 (i) Hansen, M. B.; Hubálek, F.; Skrydstrup, T.; Hoeg-Jensen, T.
329 Chemo- and Regioselective Ethynylation of Tryptophan-Containing
330 Peptides and Proteins. *Chem. - Eur. J.* **2016**, *22*, 1572–1576.
331 (9) UniProtKB/Swiss-Prot protein knowledgebase release 2015 08
332 statistics. <http://web.expasy.org/docs/relnotes/relstat.html>.
333 (10) Grotkopp, O.; Ahmad, A.; Frank, W.; Müller, T. J. J. Blue-
334 luminescent 5-(3-indolyl)oxazoles *via* microwave-assisted three-
335 component coupling–cycloisomerization–Fischer indole synthesis.
336 *Org. Biomol. Chem.* **2011**, *9*, 8130–8140.
337 (11) Hong, J. Natural Product Synthesis at the Interface of Chemistry
338 and Biology. *Chem. - Eur. J.* **2014**, *20*, 10204–10212.
339 (12) Naik, S. R.; Harindran, J.; Varde, A. B. Pimprinine, an
340 extracellular alkaloid produced by *Streptomyces* CDRIL-312: fermen-
341 tation, isolation and pharmacological activity. *J. Biotechnol.* **2001**, *88*,
342 1–10.
343 (13) Takahashi, S.; Matsunaga, T.; Hasegawa, C.; Saito, H.; Fujita,
344 D.; Kiuchi, F.; Tsuda, Y. Martefragin A, a Novel Indole alkaloid
345 Isolated from Red Alga, Inhibits Lipid Peroxidation. *Chem. Pharm.*
346 *Bull.* **1998**, *46*, 1527–1529.
347 (14) Pettit, G. R.; Knight, J. C.; Herald, D. L.; Davenport, R.; Pettit,
348 R. K.; Tucker, B. E.; Schmidt, J. M. Isolation of Labradorins 1 and 2
349 from *Pseudomonas syringae* pv. *coronafaciens*. *J. Nat. Prod.* **2002**, *65*,
350 1793–1797.
351 (15) Fresneda, P. M.; Castañeda, M.; Blug, M.; Molina, P.
352 Iminophosphorane-based preparation of 2,5-disubstituted oxazole
353 derivatives: synthesis of the marine alkaloid almazole C. *Synlett*
354 **2007**, *38*, 324–326.
355 (16) Oikawa, Y.; Yonemitsu, O. Selective oxidation of the side chain
356 at C-3 of indoles. *J. Org. Chem.* **1977**, *42*, 1213–1216.
357 (17) Roy, S.; Haque, S.; Gribble, G. W. Synthesis of Novel Oxazolyl-
358 indoles. *Synthesis* **2006**, *23*, 3948–3954.